Verde Science Inc (VRCI) 0.0008 $VRCI
Verde Science Inc. Personnel Changes
Marketwired - Fri Nov 27, 10:01PM CST
Verde Science, Inc., (OTCQB:VRCI) announces that Manfred Schauer, Paul Pelosi Jr., Dr. Shantesh Hede, and Manit Patel are no longer with the company. Verde Science will be filling these and other key positions over the next few months.
Verde Science to Sponsor/Present at the Huntington Study Group Annual Conference
GlobeNewswire - Mon Oct 12, 8:15AM CDT
(OTCQB:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabis-based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce it will be sponsoring and presenting at the twenty-third annual Huntington Study Group Conference (http://huntingtonstudygroup.org/) This year's conference, HSG 2015: Building Our Future is being held from October 21-24, 2015 at the Grand Hyatt, Tampa Bay, FL.
Verde Science Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease
GlobeNewswire - Fri Oct 09, 12:15PM CDT
Verde Science, Inc. (OTCQB:VRCI), a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon's Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.
Verde Science Appoints International Banker Manfred A. Schauer
ACCESSWIRE - Mon Jun 01, 7:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 1, 2015 / (PINKSHEETS:VRCI) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
DB: 14.40 (+0.05)
Verde Science Appoints New Chief Financial Officer with Pharmaceutical Sector Experience
ACCESSWIRE - Tue May 12, 5:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).
CRME: 5.30 (-0.14), TLM: 7.99 (unch)
Verde Science Adds John M. E. Percival to the Head of Strategic Development and Member of Board of Directors
ACCESSWIRE - Mon May 04, 5:04AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 4, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand, Ltd where he was responsible for the management of nearly a $500 million in Superannuation and private funds.
Verde Science adds Shantesh Hede, Ph.D As Director of Product Development
ACCESSWIRE - Fri Apr 10, 7:15AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 10, 2015 / (PINKSHEETS:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science's R&D programs on-site with Verde's Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.
News Release Verde Science Pursuing Development of Promising Point-Of-Care Ebola Screening Test
ACCESSWIRE - Mon Nov 10, 8:08AM CST
Image: https://www.baystreet.ca/uploads/verde.jpg
Verde Science Appoints Chief Technology Officer
ACCESSWIRE - Wed Oct 22, 8:03AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
Verde Science Inc. Personnel Changes
Marketwired - Fri Nov 27, 10:01PM CST
Verde Science, Inc., (OTCQB:VRCI) announces that Manfred Schauer, Paul Pelosi Jr., Dr. Shantesh Hede, and Manit Patel are no longer with the company. Verde Science will be filling these and other key positions over the next few months.
Verde Science to Sponsor/Present at the Huntington Study Group Annual Conference
GlobeNewswire - Mon Oct 12, 8:15AM CDT
(OTCQB:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabis-based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce it will be sponsoring and presenting at the twenty-third annual Huntington Study Group Conference (http://huntingtonstudygroup.org/) This year's conference, HSG 2015: Building Our Future is being held from October 21-24, 2015 at the Grand Hyatt, Tampa Bay, FL.
Verde Science Announces Plan to Study Cannabis Preparation for Treatment of Huntingdon's Disease
GlobeNewswire - Fri Oct 09, 12:15PM CDT
Verde Science, Inc. (OTCQB:VRCI), a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions, is pleased to announce that along with some renowned research scientists it intends to study the treatment potential of a cannabis preparation (Nabiximols) in the treatment of Huntingdon's Disease as a sponsor at 2 universities in North America. The study as currently designed will be a double-blind, placebo controlled protocol with 48 subjects.
Verde Science Appoints International Banker Manfred A. Schauer
ACCESSWIRE - Mon Jun 01, 7:01AM CDT
LAS VEGAS, NV / ACCESSWIRE / June 1, 2015 / (PINKSHEETS:VRCI) Verde Science Inc., a pharmaceutical research and development company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the appointment of Manfred Schauer as head of the Asia Pacific Region.
DB: 14.40 (+0.05)
Verde Science Appoints New Chief Financial Officer with Pharmaceutical Sector Experience
ACCESSWIRE - Tue May 12, 5:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 12, 2015 / PINKSHEETS: VRCI Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients' needs for a wide range of medical conditions is pleased to announce the appointment of David Alexander, CA as its new CFO, effective immediately. David graduated with BComm in Finance from the University of British Columbia. He has managed the rapid growth of several early stage and startup companies. As CFO of Arakis Energy Corporation, an international oil and gas development company, he managed its growth from startup to over a billion dollars in assets, and listed it on Nasdaq. Arakis was subsequently sold to Talisman Energy Inc. He was also CFO of Nortran Pharmaceuticals, Inc., a University of British Colombia based pharmaceutical Research and Development Company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran subsequently, became into Cardiome Pharma Corp., a successful Vancouver BC based pharmaceutical company (Nasdaq: CRME).
CRME: 5.30 (-0.14), TLM: 7.99 (unch)
Verde Science Adds John M. E. Percival to the Head of Strategic Development and Member of Board of Directors
ACCESSWIRE - Mon May 04, 5:04AM CDT
LAS VEGAS, NV / ACCESSWIRE / May 4, 2015 / (PINKSHEETS: VRCI) Verde Science, Inc. a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions is pleased to announce the appointment of John M. E. Percival to its Board of Directors and Head of Strategic Business Development. Mr. Percival brings over 20 years of Investment Banking, Corporate Finance and Strategic planning success to Verde. Mr. Percival was previously General Manager of Investments at Barclays Bank New Zealand, Ltd where he was responsible for the management of nearly a $500 million in Superannuation and private funds.
Verde Science adds Shantesh Hede, Ph.D As Director of Product Development
ACCESSWIRE - Fri Apr 10, 7:15AM CDT
LAS VEGAS, NV / ACCESSWIRE / April 10, 2015 / (PINKSHEETS:VRCI) Verde Science, Inc., a Pharmaceutical Research and Development Company focused on developing a portfolio of cannabinoid based prescription medicines to meet patients needs for a wide range of medical conditions, is pleased to announce the addition of Shantesh Hede, Ph.D. as Director of Product Development. Dr. Hede will be based in Mumbai, India and will direct Verde Science's R&D programs on-site with Verde's Research and Development partner, the Institute of Chemical Technology. He earned a Ph.D. in Bioengineering Systems from the MIT Portugal Program, a Master of Engineering Management from Duke University, and a Bachelors in Pharmaceutical Sciences from the Institute of Chemical Technology.
News Release Verde Science Pursuing Development of Promising Point-Of-Care Ebola Screening Test
ACCESSWIRE - Mon Nov 10, 8:08AM CST
Image: https://www.baystreet.ca/uploads/verde.jpg
Verde Science Appoints Chief Technology Officer
ACCESSWIRE - Wed Oct 22, 8:03AM CDT
Image: https://www.baystreet.ca/uploads/Verde-Scienc...-Logo1.png
